Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes

Next Previous
Trial Profile

Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Colecalciferol (Primary) ; Etanercept (Primary) ; GAD65 vaccine (Diamyd) (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms EDCR IIa

    • Most Recent Events

    • 23 Apr 2019 Status changed from active, no longer recruiting to completed.
    • 16 Apr 2019 Results presented in a Diamyd Medical AB Media Release,
    • 27 Mar 2019 According to the Diamyd Medical AB media release, 30 months results from this study are expected to be presented in the spring of 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top